| |
|
|
| Thursday, September 18, 2008 |
| SESSION I |
Chairman: Tony Green (Cambridge, UK) |
|
| 18:00 |
Myeloproliferative disorders - mutations and mechanisms |
G. Gilliland (Boston, USA) |
| 18:25 |
CML stem cells and their clinical relevance |
C. Eaves (Vancouver, Canada) |
| 18:50 |
New insights into the relationship between leukocytes and vascular events in essential thrombocythemia |
T. Babui (Bergamo, Italy) |
| 19:15 |
JAK2 Inhibitors: Phase 1 Clinical Trials |
S. Verstovsek (MD Anderson, USA) |
| 19:40 |
Finish |
|
| 20:00 |
Cocktails and Dinner |
|
|
| Friday, September 19, 2008 |
| SESSION II |
Chairman: Tiziano Babui (Bergamo, Italy) |
|
| 08:30 |
JACK2V617F and genetic instability |
W. Vainchenker (Paris, France) |
| 08:55 |
Modulation of MPD phenotype by transcription factor NF-E2 |
H. Pahl (Freiburg, Germany) |
| 09:20 |
Endothelial progenitor cells and angiogenesis in myeloproliferative disorders |
G. Barosi (Pavia, Italy) |
| 09:45 |
Short Talk |
|
| 10:00 |
Short Talk |
|
| 10:15 |
Tea |
|
| 10:45 |
Molecular and cellular pathogenesis of the myeloproliferative disorders |
T. Green (Cambridge, UK) |
| 11:10 |
Genetics of the myeloproliferative disorders |
R. Skoda (Basel, Switzerland) |
| 11:35 |
MPD disease progression: mechanisms and therapy |
M. Ruben (Mayo Clinic, USA) |
| 12:00 |
Short Talk |
|
| 12:15 |
Short Talk |
|
| 12:30 |
Lunch & Posters |
|
| SESSION III |
Chairman: Gary Gilliland (Boston, USA) |
|
| 18:00 |
Molecular and cellular mechanism of primary myelofibrosis |
R. Hoffman (New York, USA) |
| 18:25 |
Genomic features of myeloproliferative disorders |
P. Campbell (Cambridge, UK) |
| 18:50 |
Familial polycythemia vera and other germline mutations causing polycythemias |
J. Prchal (Utah, USA) |
| 19:15 |
short talk |
|
| 19:30 |
Finish |
|
| 20:00 |
Dinner |
|
|
| Saturday, September 20, 2008 |
| SESSION IV |
Chairman: Heike Pahl (Freiburg, Germany) |
|
| 08:30 |
Phenotype and genotype in the chronic myeloproliferative disorders |
J. Spivak (Baltimore, USA) |
| 08:55 |
Aberrant JAK-STAT signaling in myeloproliferative neoplasms |
S. Constantinescu (Brussels, Belgium) |
| 09:20 |
Interferon may be effective in the treatment of the cellular phase of primary myelofibrosis and reduces splenomegaly |
R. Silver (New York, USA) |
| 09:45 |
Short Talk |
|
| 10:00 |
Short Talk |
| 10:15 |
Tea |
|
| 10:45 |
Prognostic assessment in primary myelofibrosis |
F. Cervantes (Barcelona, Spain) |
| 11:10 |
Epigenetic mechanisms in the pathogenesis of primary myelofibrosis |
A. Vannucchi (Florence, Italy) |
| 11:35 |
JAK2 (V617F) allele burden, phenotype, and clinical course of myeloproliferative disorders |
M. Cazzola (Pavia, Italy) |
| 12:00 |
Short Talk |
| 12:15 |
Lunch & Posters |
|
| SESSION V |
Chairman: Radek Skoda (Basel, Switzerland) |
|
| 14:00 |
Atypical myeloproliferative disorders: pathogenesis and therapy |
N. Cross (Salisbury, UK) |
| 14:25 |
Staging and prognosis in primary myelofibrosis (PMF) |
M. Kvasnicka (Cologne, Germany) |
| 14:50 |
Novel molecular targets and targeted therapies in the myeloproliferative disorders |
R. Van Etten (Boston, USA) |
| 13:15 |
Short Talk |
|
| 15:30 |
Tea |
|
| 16:00 |
Role of tumor necrosis factor-alpha in murine JAK2 V617F-positive myeloproliferative disorders |
M. Deininger (Portland, USA) |
| 16:25 |
Mechanisms of thrombosis in myeloproliferative disorders |
B. Furie (Boston, USA) |
| 16:50 |
The apoptotic response to kinase inhibition in myeloproliferative disorder |
D. Tenen (Boston, USA) |
| 17:15 |
Manned Poster Session with refreshments |
|
| 18:30 |
Finish |
|
| 20:00 |
Conference Dinner |
|
| |
|
|